Device Trial Radar · NCT05641922
Safety and Effectiveness of BioTraceIO 360 for Planning, Monitoring and Assessment of Liver Tissue Ablation Procedures (PANORAMA2)
Last checked: Nov 20, 2026Latest source record: Nov 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Jul 2023
Primary completion
Dec 2023
Study completion Dec 2023
Sponsor
- Lead sponsor
- Techsomed Medical Technologies LTDNot on our public-company list
- Sponsor type
- Industry
- First posted
- Dec 8, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated device
- No
- Who can join
- All sexes, from 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Pilot study planned to demonstrate the safety and effectiveness of the use of BioTraceIO 360 for Planning, Monitoring and Assessment of liver tissue ablation procedures Single-center prospective single-arm clinical investigation. Sample size - 10 subjects.
Conditions
- Hepatocellular Carcinoma
- Metastatic Liver Cancer
Interventions
BioTraceIO 360Device
Use of the device for planning, monitoring and assessment of liver tissue ablations
Primary outcomes
What the sponsor says the trial is designed to measure.
- EffectivenessTime frame: 1 year
- SafetyTime frame: 1 year
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.